Skye Bioscience (SKYE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Voting matters and shareholder proposals
Election of six directors: Paul Grayson, Deborah Charych, Punit Dhillon, Annalisa Jenkins, Karen Smith, and Andrew J. Schwab, with board recommending a vote for all nominees.
Ratification of CBIZ CPAS P.C. as independent registered public accounting firm for the year ending December 31, 2026.
Approval of an amendment to increase authorized common stock from 100,000,000 to 300,000,000 shares.
Advisory vote on executive compensation as disclosed in the proxy statement.
Other business may be addressed as appropriate at the meeting or any adjournment.
Board of directors and corporate governance
Six director nominees are presented for election at the annual meeting.
Executive compensation and say-on-pay
Advisory vote scheduled on the compensation of named executive officers, following SEC disclosure rules.
Latest events from Skye Bioscience
- Shareholders will vote on director elections, auditor ratification, share increase, and executive pay.SKYE
Proxy filing16 Apr 2026 - Nimacimab plus semaglutide delivers durable, significant weight loss with strong safety and commercial potential.SKYE
Corporate presentation7 Apr 2026 - Shareholders to vote on board elections, auditor ratification, share increase, and executive pay.SKYE
Proxy filing6 Apr 2026 - Shareholders to vote on board elections, auditor, share increase, and executive pay amid clinical progress.SKYE
Proxy filing6 Apr 2026 - Nimacimab plus semaglutide delivers durable, additive weight loss with strong safety and R&D momentum.SKYE
Q4 202510 Mar 2026 - Nimacimab plus semaglutide delivers superior, durable weight loss with strong safety and financial backing.SKYE
Corporate presentation10 Mar 2026 - Phase 2 obesity trial for nimacimab advances, net loss narrows, and cash position remains strong.SKYE
Q3 202415 Jan 2026 - Phase II trial of nimacimab targets safe, effective obesity treatment with 2025 milestones ahead.SKYE
Guggenheim Global Healthcare Conference15 Jan 2026 - Phase 2 data for a novel CB1 antibody in obesity, targeting 8% weight loss, expected Q2 2025.SKYE
UBS Global Healthcare Conference14 Jan 2026